MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejcts/ezaf023

Медицинская библиотека · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025

Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management.

Hinkov Hristian, Lee Chong Bin, Greve Dustin, Klein Christoph, Kukucka Marian, Kempfert Jörg, Jacobs Stephan, Falk Volkmar, Dreger Henryk, Unbehaun Axel

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

The growing elderly population contributes to an increasing prevalence of severe degenerative native aortic valve (AV) or mitral valve (MV) disease in combination with bio-prosthetic valve failure of prior implanted (aortic or mitral) bio-prostheses, as well as concomitant failure of both aortic and mitral bio-prosthetic valves. A combined surgical AV and MV replacement carries a markedly higher risk, especially in the redo setting. Transcatheter double-valve implantation (TDVI) is emerging as a promising alternative that may mitigate the risks of redo surgery. The evidence for TDVI is very limited. This study aims to address the current gap in the literature by analysing a large institutional series of single-stage TDVI.

METHODS

Single-centre retrospective analysis of all patients (n = 13) undergoing simultaneous transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve implantation (TMVI) from October 2018 until April 2024. Primary end-points were Valve Academic Research Consortium-3 (VARC-3) and Mitral Valve Academic Research Consortium (MVARC) technical success, 30-day device success and early safety (MVARC procedural success). Secondary end-points included echocardiographic TDVI performance, adverse events, symptom change and survival.

RESULTS

The median age of patients was 77 years, with 7/13 (53.8%) females. Median EuroSCORE II was 16.9%. All patients presented with structural valve degeneration with severe haemodynamic valve deterioration according to the VARC-3 definition. Procedural outcomes showed 100% technical success. There was absence of 30-day mortality (0%). Thirty-day device success and early safety/MVARC procedural success were 100%. No major adverse events occurred. After TDVI, the median New York Heart Association functional class improved from III to II.

CONCLUSIONS

TDVI appears to be a safe and effective alternative to surgical redo double-valve replacement for selected patients. Our findings support the feasibility of TDVI with excellent early outcomes. Further prospective multicentre studies with larger cohorts are needed to validate the long-term effects and to establish TDVI as a guideline consideration.

Для цитирования: Hinkov Hristian, Lee Chong Bin, Greve Dustin, Klein Christoph, Kukucka Marian, Kempfert Jörg, Jacobs Stephan, Falk Volkmar, Dreger Henryk, Unbehaun Axel. Integrated double redo percutaneous valve replacement: simultaneous transcatheter aortic and mitral valve management.. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2025. DOI: 10.1093/ejcts/ezaf023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.